China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Rhea-AI Summary
China SXT Pharmaceuticals (NASDAQ: SXTC) will implement a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026. Class A shares will begin trading on a post-consolidation basis that day, continuing under symbol SXTC with new CUSIP G2161P173.
Before the consolidation, 105,704,077 Class A shares are outstanding; afterwards, approximately 1,321,301 Class A shares will be outstanding. Every 80 shares (or part thereof) will be combined into one share, with fractional shares rounded up. All outstanding stock options, warrants and similar rights will be adjusted proportionately.
Positive
- 1-for-80 share consolidation effective August 10, 2026, reducing outstanding Class A shares from 105,704,077 to approximately 1,321,301
- Proportionate adjustment of all stock options, warrants and other rights to purchase Class A shares maintains holders’ relative economic interests post-consolidation
Negative
- None.
Market reaction after 1-for-80 share consolidation: SXTC -49.55%
Following this news, SXTC has declined 49.55%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.7% during the session. Argus tracked a trough of -24.3% from its starting point during tracking. Our momentum scanner has triggered 107 alerts so far, indicating very high trading interest and price volatility. The stock is currently trading at $0.06.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Registered direct offering | Negative | -83.5% | Offering of units and warrants produced $9 million gross proceeds before expenses |
| Mar 23 | Share re-classification | Neutral | +5.0% | Effective re-classification created Class B shares with 50 votes per share |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two prior events showed opposite reactions: the registered direct offering was followed by -83.53%, while the share re-classification was followed by +5%.
Key Terms
cusip number financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on August 10, 2026. Upon the market opening on August 10, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P173.
Prior to the Share Consolidation, 105,704,077 Class A ordinary shares are issued and outstanding. As a result of the Share Consolidation, every 80 shares (or part thereof) will be combined into one (1) share, with fractional shares rounded up to the next whole share, and approximately 1,321,301 Class A ordinary shares will be issued and outstanding after the Share Consolidation. The Company is authorized to issue unlimited ordinary shares consisting of Class A ordinary shares, no par value per share, and Class B ordinary shares, no par value per share. All outstanding stock options, warrants and other rights to purchase the Company’s Class A ordinary shares will be adjusted proportionately as a result of the Share Consolidation.
Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.
About China SXT Pharmaceuticals Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.
China SXT Pharmaceuticals Inc.
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com
